BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 1

Founded 1993 The Breast Cancer Research Foundation ® 9 0 0 2 r e m m u

® S ®

A MessagePfrom EveIlyn LNauder, 15K Years oPf PuRttin’ OEn ThSe PiS nk Founder and Chairman In these times of economic challenges, stories about good fortune are not told as

s often, so here is my story e n i about good fortune. D . E n a l l Almost 20 years ago, even A :

o though the women’s equality t o

h movement in America had P achieved so much and, even though my friends and I were successful in business in addition to having wonderful family lives, there was an issue of great significance to women that demanded a special focus. That topic was breast

cancer. For women of my generation, we had inher - r u z ited from our mothers and grandmothers the stigma a M n i

of silence associated with such a disease. We grew v e K

up hearing the hushed voices, seeing the worried : o t

looks—but not always learning the facts. Over time o h

Dr. Larry Norton, Evelyn Lauder, Sir Elton John, Liza Minnelli and Elizabeth Hurley P we heard more about “women’s health,” but speak - ing out about breast cancer, whether you had it or “Puttin’ On The Pink” was the theme for one research project for a year. The audi - knew someone who had it, was rare. Cancer was this year’s Hot Pink Party on April 29th ence rose to the challenge and nearly still “the C-word.”The stigma and the poor progno - sis motivated me to do something meaningful to at the Waldorf=Astoria Hotel in New $300,000 in all was raised by the improve women’s lives. Let’s face it, if a woman dies York City. Thanks to generous underwrit - evening’s auction, thus assuring contin - of breast cancer, it is not only a tragedy for her, but ing from BlackBerry, Verizon Wireless ued funding for a research initiative. for all the people who know, love and depend on and many incredible friends, $4 million her…as a mother, a friend, a spouse, a boss, a sister, was raised to fuel the fight against breast Speaking about how proud she was of a daughter, or a teacher. cancer. BCRF’s great progress, Evelyn Lauder, Somebody needed to do something. In a very short Founder and Chairman continued, “But time, and with the support of my family and friends, The fun-filled evening was full of surprises. make no mistake, our Foundation’s ability in 1993 I had the organization in place to put funds Longtime BCRF supporter and the to continue to fund the projects we have for breast cancer research directly into the hands evening’s emcee, Elizabeth Hurley, kicked underway is in jeopardy without new dol - of scientists and physicians. No bureaucracy. Very off the party by raffling 11 very special lars raised by the end of our fiscal year.” low administrative costs. And with the incredible oversight of a stellar group of scientists led from Swarovski encrusted BlackBerry Pearl the start by Dr. Larry Norton. We have raised over Flip Smartphones designed by Vera The Third Annual Roz and Les $250 million since our humble beginning. My, how Wang exclusively for the event, which Goldstein Unsung Hero Award, awarded we have grown! The acceleration of knowledge were awarded to the guests at one very to an extraordinary friend who served as about the basic science of breast cancer—what it is lucky table. Then, Hugh Hildesley from a constant support system to a woman and how we can fix it, literally opened up a new era of public life and dialogue about breast cancer. Sotheby’s announced an incredible auc - who has or had breast cancer, was pre - Women do not have to hide this disease anymore, tion item: a one-of-a-kind chance to min - sented to Dr. Pat Cayne by Pat and more importantly, so many women can and do gle with Hollywood royalty, including Rosenwald. Mrs. Rosenwald acknowl - survive breast cancer—every day. This is the very access to the famous Vanity Fair Oscar edged how her dear friend “would drop best kind of good fortune. None of this would have Party, two round-trip Business Class seats whatever she was doing to help women been possible without you. to Los Angeles on Delta Air Lines, a two- just get through each day.” Dr. Cayne Please continue to support BCRF as best you can. night stay at the fabulous and very chic explained that she had her own unsung Together we can write the final chapter: a world Sunset Tower Hotel, a $3,000 allowance heroes when she was diagnosed with without breast cancer. at the Donna Karan Collection store to breast cancer 12 years ago, and now she purchase a gown, topped off by an Estée “can do for the newly diagnosed women, Lauder makeover for the night. Hildesley what my unsung heroes did for me.” “It is Evelyn H. Lauder continued the live auction by asking the about the Pat Caynes of the world—sur - audience to sponsor research time, with vivors and inspirations to us all—that the goal of raising enough money to fund fuels our determination for BCRF to be BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 2

puttin’ on the pink h h c c i i R R b b o o R R : : o o t t o o h h P Dan and Cynthia Lufkin P Leonard Lauder and Vera Wang Aerin Lauder Zinterhofer, Michael Kors and Miss USA Kristen Dalton the very best it can be,” said Myra Biblowit, BCRF President.

The highlight of the evening was Sir Elton John’s introduc - tion of his devoted friend, singing legend Liza Minnelli, whose fabulous performance was memorable. Liza stopped midway through her act, refusing to perform “New York, New York” until $50,000 was donated. Five very generous donors stood up and pledged $10,000 each so the show could go on.

Alongside Elizabeth Hurley and Sir Elton John, several stars came out in support of the Foundation, including stage and screen actors Jane Krakowski, Alan Cumming, Marilu Henner, and Jasika Nicole; 2009 Miss USA Kristen Dalton; fashion designers Donna Karan, Tommy Hilfiger, Vera Wang, Michael Kors, and Christian Siriano; fashion model h h c c i i R R Hilary Rhoda; and makeup maven Bobbi Brown. b b o o R R : : o o t t o o This year’s amazing event was made possible by the gener - h h P P William and Rachel Lauder Myra Biblowit and Jane Krakowski ous underwriting of BlackBerry, Verizon Wireless, Roz and Les Goldstein, the Hearst Corporation, Gail and Richard Siegal, and Evelyn and Leonard Lauder. The Foundation also thanks co- chairmen Bonnie Roche Bronfman and Charles Bronfman, Marjorie Reed Gordon, Cornelia Guest, Donna Karan, Kinga Lampert, Jane Lauder, Jo Carole and Ronald Lauder, Karen and William Lauder, Cynthia and Dan Lufkin, Jeanne and Herb Siegel, Ingrid Sischy and Sandra Brant, Lizzie and Jon Tisch, Vera Wang and Aerin Lauder Zinterhofer.

Jonathan and Lizzie Tisch Christian Siriano and Craig McLennan Karin and Steve Sadove

2 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 3 h h h h c c c c i i i i R R R R b b b b o o o o R R R R : : : : o o o o t t t t Roz Goldstein, founder of the Roz and o o o o h h h h P P P Jasika Nicole P Elizabeth Hurley Marilu Henner and Alan Cumming Les Goldstein Unsung Hero Award t t a r r a k S e i l u J : s o t o h p l l a d e t o n e s h i c i w r R e b h t o o R : s s o t e

l Jimmy Cayne and Unsung Hero o n h U Award recipient, Pat Cayne P Grand Ballroom, Waldorf=Astoria Pat and John Rosenwald h h c c i i R R b b o o R R : : o o t t o o h h P P Jeff Zucker and Bobbi Brown Alina Cho and Cornelia Guest

Summer Newsletter 2009 3 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 4

The Boston Hot Pink Party The Breast Cancer Research Foundation’s Boston Hot Pink Party, gen - erously underwritten by BlackBerry and Verizon Wireless, began with an informative Symposium at the Boston Harbor Hotel on May 7th.

Scientific Advisory Committee Chairman Clifford Hudis, MD, Memorial Sloan-Kettering Cancer Center, moderated the panel discus -

s Breast Cancer is Not One Disease: Now What? e sion entitled Dr. Hudis told n i D .

E the packed room that, rather than seeing the complexity of breast can - n a l l cer as a roadblock, the fact that breast cancer is a set of many diseases A : o t

o presents an opportunity to develop specifically targeted treatments. Dr. h P Drs. Joshua LaBaer, Nadine Tung, Clifford Hudis; Evelyn Lauder; Joshua LaBaer (Harvard School of Medicine) described his group’s Drs. Nancy Lin and Hyman Muss high-tech efforts, which have resulted in a “library” of over 10,000 genes that are now being explored. Their goal is to develop a simple blood test to detect the many subtypes of breast cancer at its earliest stages. Dr. Nadine Tung (Beth Israel Deaconess Medical Center) noted that her BCRF grant supports work she is doing with Dr. Stuart Schnitt; it is focused on breast cancer in women who have inherited BRCA1 and BRCA2 mutations. In particular, they seek to identify the common threads that tie this relatively rare subtype (up to about 10% of women with breast cancer) to the much more common breast cancers in the general population that act like those that are BRCA1- and BRCA2-positive. Dr. Nancy Lin (Dana-Farber Cancer Institute) described her group’s efforts to find ways to counteract brain metastases, a particular problem in some subtypes of breast cancer such as those that are HER2-positive. They are leading a clinical trial that has recruited women across the U.S. to better predict which breast cancers are most likely to spread to the brain, and to develop new treatments. Dr. Hyman Muss (University of North Carolina at Chapel Hill), has devoted his research to the study of breast cancer in older patients and noted that the average age of onset in the U.S. is 63 and is explor - ing the impact of age on all aspects of breast cancer care.

The party that followed honored and celebrated New England's premier breast cancer researchers. The 300 guests in attendance had the opportunity to take instant photos in the interactive BlackBerry photo booths. Television journalist Kelley Tuthill, of WCVB NewsCenter 5, hosted the evening. As a breast cancer survivor, Tuthill explained how she benefited from BCRF supported research: “I was diagnosed at 36 with cancer that was successfully treated with Herceptin—proof positive that research saves lives and that there is life after breast cancer.”

Larry Lucchino, President and CEO of the Boston Red Sox, received the Second Annual Boston Humanitarian Award for his admirable work with the Red Sox Foundation to support cancer research. The award was presented to Lucchino by close friends Dr. Carolyn Kaelin and Mike Barnicle, MSNBC political analyst. One very fortunate table won 12 exclusive Swarovski encrusted BlackBerry Pearl Flip Smartphones designed by Vera Wang. The event was Co-Chaired by Linda Waintrup, Elisha Daniels, and Carolyn Kaelin, MD, PHD with Vice-Chairs Sandy Krakoff and Judie Schlager. Raising over $500,000, the evening will help sustain BCRF’s investment in the best scientific tal - ent in the New England area.

Noted Bostonians in attendance were fellow Red Sox owner, John Henry, and host committee members, Linda Pizzutti and Stacey Lucchino. This year's event was made possible by the generous underwriting of BlackBerry and Verizon, The Ruth and Carl Shapiro Family Foundation, Friends of Mel Foundation, Donna and James Stearns, and David Yurman. Pictured top left: Marty Phillips, Sandy Krakoff, Judie and Larry Schlager; top right: Larry and Stacey Lucchino; Linda Pizzuti and John Henry; bottom: Linda Waintrup, Elisha Daniels and Dr. Carolyn Kaelin. All photos: Allan E. Dines

4 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 5

Conquering Breast Cancer Symposium BCRF BOARD OF On April 26th, BCRF partnered with the Avon DIRECTORS Breast Cancer Crusade and the Greater New York Evelyn H. Lauder, Chairman City Affiliate of Susan G. Komen for the Cure to Myra J. Biblowit, President present a Symposium, Conquering Breast Cancer, at the Jeanette S. Wagner, Vice President 92nd St. Y in New York City. More than 300 peo - Deborah Krulewitch, ple attended the Symposium. On the opening Secretary and Treasurer panel, BCRF Scientific Director, Larry Norton, Carolee Friedlander MD, was joined by Eric P. Winer, MD, and Paul E. Carlyn S. McCaffrey, Esq. Goss, MD, in a discussion entitled Breast Cancer: How Josie Robertson Jacki Zehner Bright is the Horizon? The speakers emphasized that there is much cause for encouragement due to recent research advances which have brought us closer to personalized treatment with targeted therapies, have unraveled clues to the molecular classification of various types of breast cancer, and have vastly improved the quality of life for women who have survived breast cancer. Globally, access to good health care is one of the chief deterrents to survival. Dr. Norton made the point that Americans spend more on soft drinks than funding from all sources for medical research; only when cancer research and good health become a national priority will cancer mortalities fall significantly.

In a seminar on inherited susceptibility to breast cancer, BCRF grantee Kenneth Offit, MD, MPH, updated the audience on recent uses of genetic information to tailor both prevention and treatment. He cautioned about "genomic tests" for diseases, conditions, and traits which are being marketed directly to consumers. He noted that many of these analyses are not of proven validity or accuracy and are usually offered without the counseling and oversight provided by health care professionals . Pictured top row: Drs. Paul Goss, Dara Richardson-Heron, Emily Senay, Larry Norton, Eric Winer; Bottom row: Carol Kurzig and Myra Biblowit

Time For Research ™. Cure breast cancer. Sponsor an hour of research. Time For Research™ is a unique online opportunity for you to sponsor an hour or more of research time and make a difference in curing breast cancer. Each hour you sponsor helps The Breast Cancer Research Foundation (BCRF) fund the best and the most innovative breast cancer research projects in the world. Sponsor a half-hour for $25, an hour for $50, two hours for $100, half a day for $600. You can choose the number of hours to sponsor. Each hour is $50. There is no limit. You can create a page and invite family, friends, or colleagues to join you. You can even dedicate your page in honor of a survivor or in memory of a loved one. Visit www.timeforresearch.org to sponsor research. BCRF LEADERS COUNCIL Gail Hilson, Chairman Marjorie Reed Gordon Memrie M. Lewis Patricia Rosenwald Roberta M. Amon Lorna Hyde Graev Nicole Limbocker Hilary Geary Ross Jessie Araskog Jamee Gregory Carol Mack June Schorr Muffie Potter Aston Audrey Gruss Hillie Mahoney Christine Hearst Schwarzman Anne H. Bass Joanne de Guardiola Ketty Maisonrouge Jeanne Sorensen Siegel Candice Bergen Candy Hamm Grace T. Meigher Nancy Silverman Magda Bleier Mai Hallingby Harrison Liz Mezzacappa Anne Sitrick Melinda Blinken Dina Merrill Hartley Muffy Miller Daisy Soros Katherine Bryan Gale Hayman Nancy Missett Louise M. Sunshine Susan Payson Burke Veronica Hearst Gigi Mortimer Felicia Taylor Catherine Cahill Marlene Hess Deborah Norville Joan H. Tisch Wendy Carduner Karen M. Karp Libby Pataki Adrienne Vittadini Patty Cisneros Mariana Kaufman Pat Patterson Barbara Walters Norma Dana Kitty Kempner Jean H. Pearman Patricia G. Warner Beth Rudin DeWoody Eleanora Kennedy Toni Peebler Thorunn Wathne Barbaralee Diamonstein- Coco Kopelman Carroll Petrie Harriet Weintraub Spielvogel Jo Carole Lauder Pauline Pitt Saundra Whitney Robin Chandler Duke Karen Lauder Patricia Quick Vivien Wyser-Pratte HRH Princess Firyal Karen LeFrak Annette de la Renta Paula Zahn Anne Eisenhower Flöttl Wendy Vanderbilt Lehman Josie Robertson

Summer Newsletter 2009 5 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 6

Q & A with Sofia D. Merajver, MD, PhD Professor of Internal Medicine, Co-Director Breast Oncology Program Director, Breast and Ovarian Cancer Risk Evaluation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

BCRF: Tell us about yourself as a scientist and how you became interested in breast cancer research. SM: I decided to be a scientist at the age of 5. I had asked my mother what I should be when I grow up and she told me to become a researcher. Mom was very wise in general, so I basically planned my whole life around becoming a scientist. Since a very early age, science has been my craft. Discovery is what I do.

My involvement in breast cancer is a bit of an accident. At the University of Michigan, I was completing my medical training and Dr. Barbara Weber [coincidentally a BCRF grantee for several years] was taking over as head of the breast cancer program. She called me while I was in the middle of a surgi - cal procedure and asked me to come work with her as the junior clinician on the breast cancer unit. That is how it start - ed; it was a good opportunity and I fell in love with every aspect of it, from the humanistic and therapeutic, to the scien - tific and global public health aspects. I am very privileged to work with patients as well as pursue meaningful research.

Did you ever seriously consider another kind of career than that of the sciences? If so, what? Well, I have had more than one scientific career so far! Does that count? My beginnings were in physics. Again, this is attributable to my mother. I was raised in Argentina in a modest home with a vast library. When I asked my mother what kind of researcher I should become, she pulled the biography of Marie Curie off the shelf and gave it to me. From that time, I was convinced that physics would be useful for anything I would do in life. I grew up and earned my PhD in physics. I became head of a lab here in the United States and was very successful with grants and research. At a certain point, however, I realized that I wanted to work on scientific problems that would impact humanity in my lifetime. I had seen very clearly how the future of physics could be applied in medicine, but quantitative methods were only rarely applied in biology then. I made a radical decision to get another set of scientific credentials. I spent the next 12 years get - ting my medical training and specialization. It was worth it.

You are known for your ongoing research on inflammatory breast cancer (IBC), both in the United States and in Africa and the Middle East. What have you and your colleagues learned about this hard-to-detect, aggressive disease? The proportion of IBC relative to the total number of breast cancers is eight to ten times greater in some parts of the world, such as Egypt, for example, than it is for women in the United States. With the help of funding from BCRF, we are trying to understand the reasons that make it so much more abundant in these places. Are there inherited factors among certain ethnic populations? Is it environmental? Studying IBC now in Tunisia, Egypt, Algeria, Morocco, Tanzania, Uganda, Ghana and Zambia helps us to better understand it in American women. And just as important, having the means to study IBC in Africa and the Middle East gives us the ability to change the oftentimes meager infra - structure of treatment where women so desperately need improved care. Cancer is a painful disease to endure without treatment; in the past, I used to see too many women in Africa and the Middle East die of IBC with little to no medical intervention. We are committed to doing the work that improves outcomes in all the locations where we study the disease.

I will never forget my first trip to Egypt in 2004. My flight arrived at 2 a.m. and they took me straight to the clinic. To my complete surprise, there were 20 patients sitting on the floor drinking tea, waiting to be seen. They all had IBC, yet they were gracious and seemed happy. I was determined to help them in any way that I could. When the doctors in the clinic showed me the first slide of a very aggressive case, I realized that I had not been thinking about IBC correctly. The features of this Egyptian case sparked in my mind, for the first time, the concept that large clusters of cancer cells in the vessels of the skin (which are celled emboli) are the ones spreading to distant organs as well; they are the very culprits of why IBC moves about the body not in individual cells the way most tumors do, but in loosely bound clusters. I could not wait to call my lab and tell them what to work on next, while I was in Egypt.

How has this discovery shaped your research goals with IBC? We very quickly zeroed in on the Rho genes, genes that in 1999 were determined to be responsible for motility, or movement of cells, both normal and abnormal. Rho genes are very important in embryonic development, but afterward, they are largely turned down, probably because in our adult life tissues do not move around so much. For IBC, it will be

6 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 7

enormously helpful to have a system of drugs that suppresses this motion. Right now, we have reached the point where we have three compounds as promising candidates. Within two to three years, if all goes well, they should be in clinical trials. We know that in several tumor types, if a lesion has hyperactive Rho genes, they are more likely to have a poorer prognosis. If we are successful with our compounds, it may lead to new interventions not only for IBC and other breast cancers, but also with pancreatic cancer and melanoma, both of which have high motility.

How close do you think we are to preventing or finding a cure for breast cancers? An absolute cure and prevention of cancer—true eradication—is still in the future. But we are very close to turning most breast cancer into a chronic illness that affects only lightly our quality and length of life. We will do this in two ways: first, by preventing metastasis. We are close to limiting the opportunities for metastasis with breast cancer. This control will be what turns breast cancer into a more manageable, long term illness rather than a life-threatening disease; this is already occurring for many patients and we need to increase the numbers of survivors with metastatic cancer, who live well with cancer kept at bay. Second, we will become better at reducing incidence in general. We have learned so much about nutrition and lifestyle that contributes to cancer; we are on the verge better public education to greatly limit cancer occurrence. And we can and should be exporting this knowledge around the globe.

How has BCRF been helpful to you? The Breast Cancer Research Foundation has helped me be the kind of scientist I dreamed of being as a child. It allows me to consider all of my creative ideas in science as potential. In other words, I am not forced to discard any potentially good ideas. I do not have to prove to BCRF that I already achieved the result in question before they fund my ideas. I can help people faster because of BCRF. This model of funding is the bridge between the safe approach to science versus the breakthrough approach to science. It allows me to mentor people and build teams. It is catalyzing. The annual meetings of BCRF grantees have often influenced what I do for the rest of the year. I learn from these colleagues and have opportunities to reach across disciplines for answers.

What are the biggest challenges in cancer research today? The biggest challenge in research today is how to build that bridge—the one that spans the safe approach to doing science, which is the way most funds are allocated, to the breakthrough approach to doing science, which is the way BCRF funds are allocated. We need to find ways to have more of our creativity as scientists take the lead throughout cancer research in gen - eral. The bridge has to span disciplines and teams of people and countries; the disease of cancer has no political boundaries, but cancer care and research do, and we must change that. BCRF is helping me and many others accomplish this.

The Symposium and Hot Pink Luncheon in Palm Beach The Flagler Museum was the sun-filled set - ting for the Sixth Annual Palm Beach Symposium and Hot Pink Luncheon on t

r February 9th. The day commenced with a a h e

p thought-provoking panel discussion entitled a C

n How Science is Revolutionizing Our Approach to e i c

u Breast Cancer L

: , moderated by BCRF Scientific o t o

h Director, Dr. Larry Norton, who opened the P proceedings by highlighting BCRF’s empha - sis on creativity, giving researchers the freedom to follow their vision. “Our understanding of the biology of cancer is leading us to the point of major advances….Cancer can be cured. What makes this era different from what has come before is that our discoveries are yielding fundamental knowledge, so it’s not just trial and error,” Dr. Norton explained. Panelists included Drs. Clifford Hudis, William Kaelin, Marc Lippman and Kornelia Polyak, all BCRF grantees. Thanks to the leadership of co-chairmen Donna Acquavella, Sandra Krakoff, Evelyn Lauder, Hillie Mahoney, Pauline Pitt, Tricia Quick, Hilary Geary Ross, and Frances Scaife, the event raised over $300,000. Generous underwriting was made possi - ble by Evelyn and Leonard Lauder, NetJets and UBS. A kick-off dinner celebrating the underwriters and leadership was hosted by Advisory Board member Tricia Quick. Pictured left: Drs. Marc Lippman, Clifford Hudis; Evelyn Lauder; Drs. Kornelia Polyak, Larry Norton; Peg Mastrianni and Dr. William Kaelin; Pictured right: Tricia Quick and Michele Kessler

Summer Newsletter 2009 7 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 8

The Breast Cancer Research Foundation: What We’ve Accomplished The Breast Cancer Research Foundation was established in 2 Reports of the first clinical studies in breast cancer stem 1993, with the intention of bringing about a cure for breast cells this year cited the important 2003 discovery of cancer in our lifetime. Larry Norton, MD, of Memorial the fundamental properties of the cells that are Sloan-Kettering Cancer Center, has directed the the very roots of breast cancers —research con - Foundation’s scientific activities since its beginnings. In 2002, ducted with BCRF funding (Michael Clarke, MD, BCRF expanded its mission to include prevention as well as Stanford University, Stanford, CA, Jenny Chang, MD, cure, reflecting the direction of its research grants aimed at and Kent Osborne, MD, Baylor College of Medicine, prevention as well as treatment. Since inception, BCRF has Houston, TX). Also in 2008, BCRF researcher Robert increased its annual funding level more than 200 times over, Weinberg, PhD, of the Whitehead Institute, Cambridge, with grants of $34.5 million awarded to 166 scientists based MA learned that in the process of metastasis, the cells in 10 countries (and with projects extending to 28 countries) that make up breast cancer tumors acquire can - in October 2008—a very long way from the $159,000 to cer stem cell traits, making them more tena - eight researchers awarded in 1994. cious. This finding, along with other investigations of the origin of breast cancer stem cells, namely, how The following 15 areas of BCRF research accomplish - tumors seed themselves (Larry Norton, MD, Memorial ment have laid the foundation for breast cancer pre - Sloan-Kettering Cancer Center) and basic molecular vention and cure: research on breast cancer stem cells, makes BCRF a leader in determining the weaknesses of the cells that 1 BCRF is the lead organization in funding give rise to breast cancer. research on genetic susceptibility in breast can - cer. Since 1997, The New York Breast Cancer Study, 3 Described by The New York Times as a “break - under the direction of Mary-Claire King, PhD, through” treatment for breast cancer, University of Washington, Seattle, and Joan Marks, MS, Herceptin’s discovery and refinement for various Sarah Lawrence College, Bronxville, NY, has been iden - stages and forms of cancer has been an ongoing tifying the genes underlying the inherited risk of breast BCRF endeavor. cancer among women of Ashkenazi Jewish ancestry. I 2001 New England Journal of Medicine describes Working in tandem since 2001, the Israeli Breast Cancer the value of trastuzumab (marketed as Herceptin), Study, under the direction of Ephrat Levy-Lahad, MD, a monoclonal antibody directed against the HER2 Shaare Zedek Medical Center, Jerusalem, determines receptor that improves outcomes, including sur - breast and ovarian cancer risk in the Ashkenazi popula - vival, for patients with metastatic HER2-positive tion in Israel by identifying BRCA1 and BRCA2 carriers disease. (Larry Norton, MD, Memorial Sloan- through healthy males. This program is a model for Kettering Cancer Center, co-authored the initial genetic breast cancer prevention screening in general. In publication). addition, BCRF researchers have made the following I 2005 Several large multi-center randomized controlled contributions: trials show that adjuvant trastuzumab can decrease the I 2002 The finding that breast cancer is a collection of risk of recurrence for patients with HER2-positive diseases with different patterns of gene activity, which early-stage breast cancer by 50 percent. (Edith Perez, relate directly to determining prognoses and selecting PhD, Mayo Clinic, Jacksonville, FL) most appropriate treatments. (Charles Perou, PhD, I 2007 In the case of inflammatory breast cancer, University of North Carolina, Chapel Hill, and many administering Herceptin before surgery in addition to others from BCRF) chemotherapy improves the likelihood of a disease- I 2006 The collection of more than 1,300 human genes free survival. (Jose Baselga, MD, Vall d'Hebron related to breast cancer, which is now available to sci - University Hospital, Barcelona, Spain) entists worldwide for studying breast cancer. (Joan Brugge, PhD, and Joshua LaBaer, MD, PhD, Harvard 4 In 2007, the same year that ASCO and the ACS recom - Medical School, Boston) mend magnetic resonance imaging (MRI) tests for women I 2008 New genetic risk markers for breast cancer dis - considered at high risk for breast cancer and in women covered and sister study searching for new genetic pro - with newly diagnosed breast cancer, a specialized MRI tective markers for breast cancer is launched (Kenneth test for women with fast-growing breast tumors Offit, MD, MPH, Memorial Sloan-Kettering Cancer was developed with BCRF funding (Laura Esserman, Center, New York) MD, MBA, University of California/San Francisco). Tracking the presence of specialized immune system cells always found in the same cellular “neighborhood” where

8 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 9

fast-growing tumors occur, BCRF researchers con - Johns Hopkins University, Baltimore, MD), uniting the firmed a new marker for breast cancer screening efforts of 14 leading breast cancer research cen - that may also help doctors better decide which treatments ters in the U.S. The mission is to reduce the burden of to give patients. breast cancer by using a collaborative and multidiscipli - nary approach to improve the understanding of breast 5 A tumor’s blood supply system is one of its most vulner - cancer biology and test new therapeutic strategies. This able points, and a promising new area of cancer research is a savvy method of extending the value of the field’s is called anti-angiogenesis treatment. BCRF-funded the financial and intellectual resources. After BCRF’s found - field’s founder, the late Dr. Judah Folkman, MD, of ing support, the Komen Foundation and the Avon Children’s Hospital, Boston from 1998, and helped his Foundation joined in and have contributed ongoing sup - and other laboratories toward the development of mul - port to TBCRC as well. tiple drugs that can keep breast cancer cells in a dormant I In three years, TBCRC members have completed a state by inhibiting the growth of blood vessels. (Robert study of chemotherapy and a biological agent, cetux - Benezra, PhD, Memorial Sloan-Kettering Cancer imab, for "triple negative" breast cancer, the kind of Center, New York, Gabriel Hortobagyi, MD, and Mien- breast cancer that cannot be treated by current biolog - Chie Hung, PhD, University of Texas MD Anderson ical agents like endocrine therapy. Cancer Center). In 2005, two clinical studies con - I Studies examining new combinations of new biologi - ducted by BCRF researchers showed improved cal therapies targeting the estrogen receptor and the outcomes for breast cancers treated with HER2 proteins have begun. Avastin, an anti-angiogenesis drug, in conjunc - I Work to identify new markers in the blood that might tion with Taxol. (Kathy Miller, MD, and George aid in breast cancer management is underway. Further Sledge, MD, Indiana University School of Medicine). proof of BCRF’s integral support of clinical trials is demonstrated by its grant support of all relevant NCI 6 In 2006, the development of gene-based approaches to cooperative groups: the American College of Surgeons predict which women with breast cancer will benefit Oncology Group, Cancer and Leukemia Group B, the most from treatment with tamoxifen or from aromatase Eastern Cooperative Oncology Group, North Central inhibitors has improved both the application of aro - Cancer Research Group, the Southwest Oncology matase inhibitors and advanced the field of person - Group, and the National Surgical Adjuvant Breast and alized medicine, tailoring treatment to patients’ Bowel Project, as well as the oversight group, the tumors and their individual genetic make up . Coalition of National Cancer Cooperative Groups. (Benita Katzenellenbogen, PhD, University of Illinois at Urbana-Champaign, Christos Sotiriou, MD, PhD, Jules 9 In a prescient move, BCRF began a program of interna - Bordet Institute, Brussels, Belgium, and Marc Lippman, tional research funding, growing from its first internation - MD, University of Miami, FL). al grant in 2001 to Ephrat Levy-Lahad in Israel, to grants including more than two dozen countries in 2008. While 7 Up to 40 percent of women treated for estrogen recep - other groups have funded international breast cancer tor-positive (ER+) breast cancer with tamoxifen will advocacy projects and international research, BCRF progress to incurable disease. In 2007, a genomic test was the first private organization to fund scientif - revealed 62 determining genes for ER+ breast ic research on breast cancer internationally. cancer and identified two sub-groups of ER+ I Results include improving standards of care in numer - tumors. (Christos Sotiriou, Institut Jules Bordet). He ous breast cancer populations in South America, The and his colleagues are improving the selection of patients Middle East and Africa, as well as research break - who will benefit from tamoxifen treatment, and using throughs in inflammatory breast cancer, breast cancer their new data about different types of ER+ tumors, to genetics and the underlying molecular conditions of develop effective treatments beyond tamoxifen—another breast cancer. improvement in personalized medicine that will save I In 2005, The Breast International Group (BIG) in lives. The genomic tests are being translated into com - Belgium partnered with The Breast Cancer Intergroup mercially viable diagnostic tools for ER+ breast cancers. (TCBI). This collaboration—similar to TBCRC, but at an international level—forged new acceleration of clin - 8 BCRF has established a leadership role in breast cancer ical trials and translational research drawing from the clinical trials. In 2005, BCRF created the Translational resources of many countries (Martine Piccart-Gebhart, Breast Cancer Research Consortium (TBCRC) (coordi - MD, PhD, TRANSBIG and Jules Bordet Institute, nated by Nancy Davidson, MD, University of Brussels, Belgium, and Daniel Hayes, MD, University of Pittsburgh, Pittsburgh, PA and Antonio Wolff, MD, Michigan, Ann Arbor, MI).

Summer Newsletter 2009 9 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 10

10 Not only have BCRF researchers discovered connections tified and described. (Robert Weinberg, Joan Brugge between common nutrients such as vitamin D and dis - and Charlotte Kuperwasser, PhD, Tufts University School ease, they have systematically determined the of Medicine, Boston). New therapies designed to impede links between metabolism, diet and physical EMT may avert disease progression and metastasis. activity in relation to breast cancer risk, recur - rence and survival . 13 Starting in 1998, BCRF researchers have helped I 1996-2003 BCRF research teams confirm that main - reclassify human breast cancers into a greater taining a normal body weight can have a profound number of subtypes and in turn established influence on breast cancer incidence and prognosis, valuable guidelines for treatments according to even in genetically pre-disposed women. (Mary-Claire molecular profiling of tumors. In addition, several King, PhD, Joan Marks, Pamela Goodwin, MD, BCRF researchers are taking the increased characteriza - University of Toronto/Mount Sinai Hospital, tion of tumor types and applying their data across pop - Ontario, Canada, and Stephen Hursting, PhD, MPH, ulations to determine breast cancer susceptibility. University of Texas at Austin) (Charles Perou, Jenny Chang, and Dirk Iglehart, MD, I 2006 The discovery that milk consumption increases and Andrea Richardson, PhD, Brigham and Women's growth hormone levels, which might explain an associ - Hospital/Harvard Medical School, Boston). ation of pre-pubertal dairy intake and breast cancer. (Walter Willett, MD, DrPH, Harvard School of Public 14 In 2003, a novel screening technology was devel - Health, Boston). oped—representational oligonucleotide microar - I 2008 Low levels of Vitamin D are associated with ray analysis—using biopsied breast tissue that increased risk of breast cancer (Pamela Goodwin, MD). can track the genetic “mistakes” that may lead I 2009 New BCRF studies to determine appropriate to cancer with very high accuracy . This ROMA levels of vitamin D are beginning, due to the possible technology is also applied to the differences in the DNA risks associated with levels of the nutrient that may be of normal cells, aiding in the search for both tumor dif - too high. ferences and individual genetic and metabolic differ - ences that are helping guide breast cancer treatments. 11 Starting in 2001, the science of survival and quality of (Michael Wigler, PhD, Cold Spring Harbor Laboratory, life for breast cancer patients was developed with BCRF Cold Spring Harbor, NY). funding. (Patricia Ganz, MD, University of California, Los Angeles). As more women survive breast cancer, sci - 15 Half of all women with breast cancer are 65 or older at entific understanding of factors that hinder or enhance diagnosis, and that percentage is known to be rising. survival is crucial. A group of BCRF researchers sys - Most clinical trials in breast cancer historically exclude tematically study exercise, reproductive health women who are considered senior citizens, yet a healthy and side effects such as lymphedema. Through 65-year-old has a life expectancy of at least another 20 these studies, they have significantly improved years. Since 1995, BCRF researchers have been and continue to improve the quality of life for studying the needs of elderly breast cancer breast cancer survivors. Ganz has also led findings patients, and documenting the fact that theirs is concerning the biological basis for several of the adverse a unique complex of diseases, and that older effects of breast cancer treatment: early menopause, patients are less likely to be offered participa - fatigue and cognitive problems. tion in clinical trials than younger patients . The I In a related project begun in 2003, Harold Freeman, results of one recent study in older women by a BCRF MD, of the Ralph Lauren Cancer Center for Cancer researcher and leader in the area of breast cancer treat - Care and Prevention, New York, developed the role of ment among the elderly show that they are well-served Patient Navigators in the culturally-sensitive coordi - by standard chemotherapy (Hyman Muss, MD, nation of care for women with and at risk for breast University of North Carolina, Chapel Hill, NC). cancer.

12 Different types of cells within the primary tumor, called the tumor microenvironment, can and should be target - ed to avoid progression and metastases. In 2007, a pro - gression of breast cancer at the molecular and h c

cellular level known as the epithelial-mesenchy - i R b

mal transition (EMT), a process that allows can - o R : o t

cerous cells to invade and metastasize, was iden - o h P

10 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 11

Letter From Our President EXECUTIVE BOARD It is a bittersweet moment in breast cancer research funding. We have OF SCIENTIFIC come so far with the science and the improved survival and quality of t

t ADVISORS a r

r life for women. But we are not finished. The so-called “triple negative” a k

S Chairman and Scientific Director e

i breast cancers continue to vex scientists and cut short women’s lives. l u J Larry Norton, MD : o t Metastasis is proving more complicated to control than we expected, Memorial Sloan-Kettering o h P even in the light of some exciting breakthroughs. Cancer Center

There are a lot of hurdles to overcome, including several years of declining government Members support of breast cancer research, the lack of incentives for researchers to enter the field Nancy E. Davidson, MD and have the means to pursue important questions from a young age, and even a looming University of Pittsburgh shortage of oncologists. And we hear every day about the continued economic downturn. Cancer Institute We have all heard the sad news about endowments being reduced, and the fact that a Peter Greenwald, MD, Dr. PH number of charities unwittingly placed their funds in the hands of untoward investors. National Institutes of Health, Division of Cancer Prevention and Control We have neither of these problems at The Breast Cancer Research Foundation. Fortunately, we have not made any bad investments; only good ones. We spend all the Gabriel N. Hortobagyi, MD money we raise each year on research and administering that research. We have complete University of Texas transparency about where our money goes. We believe this is the most credible way to MD Anderson Cancer Center operate because it brings us to cures and prevention faster. Of course, we are watching this year’s developments like everyone else, especially because we must create our revenues SCIENTIFIC ADVISORY anew from year to year. Even for a stable, well-established foundation with an impeccable COMMITTEE reputation of achievement, this year is unlike anything we have experienced before. While it is encouraging that throughout the worst economic news of the fall and into the new Chairman Clifford Hudis, MD year we have steadily raised money, without new gifts from some generous supporters Memorial Sloan-Kettering before our fiscal year closes on June 30, we will not achieve last year’s record-breaking Cancer Center $40 million this year, needed to sustain our current level of grant support. But one thing never changes. Evelyn Lauder and the scientific advisors of BCRF have created the Members greatest brain trust in breast cancer research ever assembled; we will do everything in our Patricia A. Ganz, MD power to keep it going strong. We will continue to give our scientists the freedom to Jonsson Comprehensive Cancer Center pursue answers to the most important questions about breast cancer. We are 100 percent University of California, Los Angeles committed to this and we hope you are too. Judy E. Garber, MD, MPH Dana-Farber Cancer Institute Remember, we need your help now more than ever. Much is at stake. With a gift to Harvard Medical School BCRF you can be sure that your contribution is truly leveraging lifesaving research. Lajos Pusztai, MD, D.Phil Sincerely, University of Texas MD Anderson Cancer Center

Vered Stearns, MD Myra J. Biblowit The Johns Hopkins University School of Medicine ADVISORY BOARD Arlene Adler Lorna Hyde Graev Laura Lassman Judith P. Schlager Roberta M. Amon Betsy S. Green Ellen Levine Muriel Siebert Melinda Blinken Bette-Ann Gwathmey Cynthia Lufkin Anne Sitrick Mary Bryant Lori Hall Marisa Acocella Marchetto Joanne Smith Susan Payson Burke Ronnie Heyman Ellen Odoner, Esq. Erana Stennett Darlene Daggett Gail Hilson Mary Alice Pappas Arlene Taub Rena Rowan Damone Susan B. Hirschhorn Alexandra Penney Linda Waintrup Elisha Daniels Robin J. Kemper Winifred Gorlin Phillips Cathy Weinroth Ute Dugan, MD, PhD Kitty Kempner Jane Pontarelli Harriet Weintraub Suzanne Elson Rochelle Kivell Patricia Quick Candace King Weir Anne Eisenhower Flöttl Sandra Krakoff Lynda Resnick Sara Wolfensohn Amy P. Goldman, PhD Sheila C. Labrecque Wendi Rose Rhonda S. Zinner Barbara Goldsmith Elyse Lacher Patricia Rosenwald Roslyn Goldstein Maralyn Lakin Valerie Salembier Marjorie Reed Gordon Kinga Lampert Suzanne Santry

Summer Newsletter 2009 11 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 12

play for p.i.n.k.

Dolphin Head Golf Club, Hilton Head Island, SC

Play for P.I.N.K. (PFP) continues to expand into new states and clubs every day. Why not become part of this winning team, right in your own neighborhood, with your friends and colleagues? In addition to golf and tennis, we continue with other wonderful PFP events such as swimming, card games, dinner/dances, and PFP cocktail parties – all raising money for BCRF.

PFP’s commitment to donating 100% of funds raised would not be possible without their generous title sponsor, Bloomberg. The Estée Lauder Companies and Wilson Sporting Goods continue to donate products for all events.

We are indebted to the extraordinary group of PFP volunteers–the board, chairwomen and participants. Last year, over 17,000 people came forward to give hope their best shot by “Playing something for P.I.N.K.” Thanks to their generosity, PFP is currently funding 12 of the nation’s leading breast cancer researchers with their $3 million donation, bring - ing their cumulative donation to the Foundation to $15.75 million. Paddle Tennis in Connecticut

Think P.I.N.K. Be in the know. Visit www.playforpink.org or call me at 646.497.2605 to find out about ongoing achievements, happenings, how to register for a tournament, how to organize a tournament, or how to make a donation.

Sincerely, Stephanie Hamburger Director, Play for P.I.N.K.

JUNE 2 Hampshire (NY), 3 Ridgewood (NJ), 4 Ramsey (NJ), 7 Round Hill (CT), 9 Edgewood Valley (IL), 10 Burning Tree (CT), 10 Forsgate (NJ), 10 Plandome (NY), 10 Silver Spring (CT), 16 Dellwood (NY), 16 Hinsdale (IL), 16 Montammy (NJ), 16 Mt. Kisco (NY), 16 Royal Melbourne (IL), 17 Baltusrol (NJ), 17 Waushara (WI), 18 Alpine (NJ), 18 Glendale (WA), 18 Hampton Hills (NY), 22 Tamarack (NY), 25 Bamm Hollow (NJ), 25 Riverside (IL), 27 Forest Hill (NJ), 30 Arcola (NJ), 30 Hackensack (NJ), 30 Knickerbocker (NJ), 30 Rolling Green (IL), 30 Willow Ridge (NY)

JULY 2 CC of Darien (CT), 2 Panther Valley (NJ), 6 Bailiwick (CT), 7 Fairview (NY), 7 New Albany (OH), 7 Stanwich (CT), 8 Glen Ridge (NJ), 8 Shore & Country (CT), 9 Edgewood (MI), 9 Elmwood (NY), 9 Salem (NY), 11 Ann Arbor (MI), 11 Sweetbriar (OH), 12 Sleepy Hollow (NY), 14 Old Oaks (NY), 14 Ravinia Green (IL), 14 Shackamaxon (NJ), 15 Bonnie Briar (NY), 15 Seawane (NY), 15 Telluride (CO), 15 Tuxedo (NJ), 15 Winged Foot (NY), 16 Baltusrol (NJ), 16 Edgewood (NJ), 17 Leewood (NY), 17 Niagara Falls (NY), 18 Coppertop (OH), 20 Rye (NY), 21 Hatherly (MA), 21 Hillcrest (IL), 23 Normanside (NY), 28 Crestmont (NJ), 28 Maplewood (NJ), 28 North Fork (NY), 28 Preakness Hills (NJ), 28 Tamarack (NY), 31 Brae Burn (NY)

AUGUST 4 Cedar Hill (NJ), 4 Middlebay (NY), 5 Ardsley (NY), 5 Knob Hill (NJ), 5 Powelton (NY), 5 Elk River (NC), 6 Greenbrook (NJ), 7 Hideout (PA), 9 Essex County (NJ), 11 Cohasset (MA), 11 Mountain Ridge (NJ), 12 Ridgeway (NY), 12 Wildwood (NY), 13 Mauh Nah Tee See (IL), 17 Lords Valley (PA), 18 Apple Hill (NH), 18 Manasquan River (NJ), 18 Minisceongo (NY), 18 Suneagles (NJ), 18 Upper Montclair (NJ), 20 Beech Mountain (NC), 20 Mahopac (NY), 30 Lexington (MA)

SEPTEMBER 11 Plateau (WA), 15 Essex Fells (NJ), 16 Coveleigh (NY), 22 Blackrock (MA), 22 Fairmount (NJ), 22 Montclair (NJ), 30 Cohasset (MA)

OCTOBER 5 Indian Pond (MA), 8 Pink Championship Playoffs (NJ), 13 Pink Championship Playoffs (NY/CT), 14 Belfair (SC), 16 Wee Burn (CT)

12 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 13

The Housewares Charity Foundation Gala events The 12th Annual Housewares Charity Foundation Gala on March 23rd in Chicago was an evening full of celebration. Tim Adams, Chief Private Brand Officer, Macy’s Private Brands, was honored as the Lifetime Humanitarian and Lyn Kirby, President and Chief Executive Officer, Ulta Salon, Cosmetic and Fragrance, Inc., was bestowed with the Creative Leadership Award. BCRF, the legacy charity of the Housewares Charity Foundation since 2001, was thrilled to be named the sole chari - table recipient this year. As the Housewares Charity Foundation’s slogan states, “Giving Begins at Home.” This amazing gala raised a record-breaking $1.8 million for BCRF, bringing the Housewares Charity Foundation’s cumulative donation to the Foundation to over $8 million. This year, their contribution will support seven ground-breaking research initiatives. Pictured left: Janet Grove and Tim Adams; Pictured right: Lyn Kirby and Evelyn Lauder

QVC Presents “FFANY Shoes on Sale” Fanciful shoes, fabulous deals and fantastic fundraising were the themes of the 15th Annual QVC Presents “FFANY Shoes on Sale” gala on October 15th. From the shoe salon to the simultaneous televised live QVC broadcast, BCRF received $307,075 to continue support of “The First Step Award.” This Award funds a research project under the joint direction of Dr. Larry Norton of Memorial Sloan- Kettering Cancer Center and Dr. Rachel Hazan of Albert Einstein College of Medicine, exploring why breast cancers sometimes spread to other parts of the body. The research is aimed at speeding the development of targeted therapies to eliminate metastasis. Pictured: Ronald Fromm, Chairman Fashion Footwear Charitable Foundation; Michael George, President/CEO QVC; Evelyn and Leonard; Joseph Moore, President/CEO, FFANY

A Special Valentine’s Day Gift Barry Manilow fans were rocking at the “ULTIMATE MANILOW: The Hits…and then some” concert at Nassau Coliseum in Long Island, NY on February 14th. Thanks to the h c i

R generosity of Joe and Arlene Taub, Barry Manilow entertained the crowd with his b o

R favorite songs making Valentine’s Day 2009 a day to remember. Pictured: Barry Manilow (C) with : o t

o Arlene and Joe Taub h P

Pink Ribbon Programming on QVC On May 1st, in honor of Mother’s Day, QVC aired six very special hours of Pink Ribbon programming featuring beauty, jewelry and gift items for the home to benefit BCRF. The items were beautiful, and at least ten percent of each purchase will be donated to the Foundation. It is estimated that the Pink Ribbon shows raised approximately $100,000 as well as increased aware - ness about BCRF and the need to fund life-saving research.

Summer Newsletter 2009 13 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 14

events A Cure In Our Lifetime Breakfast Featuring Dr. Sanjay Gupta BCRF is a beneficiary of the 12th annual Chappaqua “A Cure in Our Lifetime” spring breakfast. The event, held on May 15th at the Whippoorwill Club and organized by a dedicated committee, had an overflow crowd of more than 200 attendees and raised $35,000. The inspirational keynote speaker was Dr. Sanjay Gupta, CNN chief medical correspondent, whose mother’s experience with breast cancer was a deciding factor to change his career from neurosurgery to healthcare journalism where he can disseminate news about healthy living to many thousands of people. Pictured: Dr. Sanjay Gupta and Myra Biblowit (C) with Chappaqua Host Committee members

2009 Challenge of the Americas The Eighth Annual Challenge of the Americas competition and Challenge Gala was held March 7th at the International Polo Club in Wellington, Florida. Top riders and trainers of the dressage world, along with generous sponsors and supporters, enjoyed dinner and dancing. Challenge of the Americas chairman Mary Ross expressed her gratitude for the great turnout: "This competition is

e dedicated to all those who face their own challenge in the fight against breast cancer. We all need l k c i t

S to work together and support breast cancer research. If we do, we will win the battle." Laura J n a

s Lassman, President of Play for P.I.N.K., continued: "We are so proud of Mary for supporting such u S : o

t a great cause. This year was absolutely incredible." The benefit raised over $200,000 for BCRF. o h

P Pictured: Jane Hannigan, Maksymillion

The Pink Agenda’s Annual Spring Gala An overflow crowd attended the Pink Agenda’s Annual Spring Gala on May 14th in New York City. Hoda Kotb, breast cancer survivor and “Today” show host, was hon - ored, and BCRF was the primary beneficiary. Leading this organization of young profes - g i a

r sionals committed to engaging today’s generation for tomorrow’s cure are founders, C e

o Marisa Renee Lee and Liana Guzman. Event co-chairs were Lauren Pierce Bush and J : o t

o Amanda Hearst. Visit www.thepinkagenda.org to learn more. Pictured: Alexa Lynch, Jacquelyn M. h P Scharnick, Liana M. Guzman and Marisa Renee Lee

Pink is The New Black 2 200 Scarsdale High School students, parents, and teachers gathered at Bloomingdale’s in White Plains, NY on May 16th for ‘Pink Is The New Black 2: Strutting Our Stuff to Eliminate Breast Cancer.’ The fashion show was organized and executed by Zoe Katz and Danielle Pack, and also included a raffle and shopping event. The event raised over $15,000 for BCRF and was dedicated in memory of Zoe’s mother, Patti Katz, and Danielle’s aunt, Jane Pack Dessau. Pictured: Danielle Pack and Zoe Katz

14 The Breast Cancer Research Foundation BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 15

thank you t t a r r a k S e t i t l a u J r r : a o t k S o h e i P l u J : o t

Brighton guests flanking Evelyn Lauder (in pink o h top), Myra Biblowit (in orange), and Terri and P Jerry Kohl (C), from Brighton. Joanne Smith (4th from L), with enthusiastic Delta employees, presented a check to Myra Biblowit and Evelyn Lauder. Delta raised $500,000 for BCRF.

Kim Martilla and the Worcester Polytechnic Institute Engineers softball team wore pink shoelaces and As a prelude to the Boston Hot Pink Party, donated $5 for every David Yurman, fine jewelry designer, held an game they won to event at the company’s boutique in Boston. Pictured: Pauline Alighieri, Myra Biblowit, Elisha Daniels, Kelley BCRF. Tuthill, Heather Blaine, Stephanie Millon.

In memory of her mother, 13-year-old Sydney Metzger created and organized ‘Ribbons for Robin,’ a community walk, and raised $15,000 from the sale Josh Lauder raised over $2,000 for BCRF as part of his of baked goods, shirts and bracelets. philanthropy class project at Gideon Hausner Jewish Day School in Palo Alto, CA. Pictured: Evelyn Lauder and Josh Lauder

Summer Newsletter 2009 15 BCRF_summer2009Newsletter:Layout 1 6/15/09 7:00 AM Page 16 your calendar of PINK events JULY Monday, 13: Key Foods Golf Outing, Pine Hollow Country Club, NY Sunday, 26: Danskin Women’s Triathlon, Webster, MA AUGUST Sunday, 2: Danskin Women’s Triathlon, Philadelphia, PA Sunday, 16: Danskin Women’s Triathlon, Seattle, WA Monday, 17: Play for P.I.N.K. 7th Annual Golf and Tennis Classic, Old Westbury Country Club, NY Saturday, 22: Day at the Races, Saratoga, NY SEPTEMBER Sunday, 13: Danskin Women’s Triathlon, Sandy Hook, NJ Sunday, 27: Danskin Women’s Triathlon, Pleasant Prairie, WI OCTOBER Sunday, 4: SHAPE Pilates for Pink, Union Square Park, New York, NY Wednesday, 7: Power Wednesday Sale, Bon-Ton Stores, nationwide Saturday, 10: “Steps to the Cure,” Baltimore Country Club, Baltimore, MD Saturday, 10: Trek Breast Cancer Awareness Ride, Trek Dealers across the U.S. and Canada Tuesday, 13: QVC Presents FFANY Shoes on Sale, Rose Hall, Lincoln Center, New York, NY Thursday, 15 – Sunday, 18: Saks Fifth Avenue Key To The Cure Shopping Event, all Saks Fifth Avenue stores Wednesday, 28: BCRF Symposium and Annual Awards Luncheon, The Waldorf=Astoria, New York, NY

Charity Navigator Gives BCRF 4-Star Rating Again! For the eighth consecutive year, The Breast Cancer Research Foundation has received the coveted top 4-star rating from Charity Navigator for its “ability to efficiently manage and grow its finances.” Less than 1% of charities evaluated, in fact only ten out of 5,410 organizations, have received eight consecutive 4-star evaluations. This confirms that The Breast Cancer Research Foundation consistently executes its mission in a fiscally responsible way, and outperforms most other charities in America. “This ‘exceptional’ designation from Charity Navigator differentiates The Breast Cancer Research Foundation from its peers and demonstrates to the public it is worthy of their trust,” wrote Ken Berger, President and Chief Executive Officer of Charity Navigator.

2010: SAVE THE DATES The Breast Cancer Research Foundation NON-PROFIT ORG. Monday, February 8, 2010 60 East 56th Street, 8th Floor The Symposium and Hot New York, New York 10022 US POSTAGE PAID Pink Luncheon, NEW YORK, NY Flagler Museum, Palm Beach, FL PERMIT NO. 7131 Tuesday, April 27, 2010 The Hot Pink Party, The Waldorf=Astoria, New York, NY

The BCRF Contact Info Breast Phone: 646.497.2600 Cancer Research

Toll-Free: 866.FIND.A.CURE Foundation TM

email: [email protected] ADDRESS SERVICE REQUESTED www.bcrfcure.org